StockData
Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc. (RARE) stock

RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$16.48−0.74 (-4.30%)

Close on Nov 20, 2026Market cap $1.62BP/E –Yield –

Ultragenyx Pharmaceutical revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Ultragenyx Pharmaceutical's revenue for the twelve months ending Jun 30, 2026 was $717.21M, up 17.5% year over year. For fiscal 2025 it was $673.00M, up 20.2% from the year before. The highest annual figure on record is $673.00M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$673.00M+20.2%
FY2024Dec 31, 2024$560.00M+29.0%
FY2023Dec 31, 2023$434.00M+19.5%
FY2022Dec 31, 2022$363.33M+3.4%
FY2021Dec 31, 2021$351.41M+29.7%
FY2020Dec 31, 2020$271.03M+161.3%
FY2019Dec 31, 2019$103.71M+101.4%
FY2018Dec 31, 2018$51.50M+1871.5%
FY2017Dec 31, 2017$2.61M+1863.9%
FY2016Dec 31, 2016$133.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$214.00M+28.1%
Q1 FY2026Mar 31, 2026$136.00M-2.2%
Q4 FY2025Dec 31, 2025$207.28M+25.9%
Q3 FY2025Sep 30, 2025$159.93M+14.7%
Q2 FY2025Jun 30, 2025$167.00M+13.6%
Q1 FY2025Mar 31, 2025$139.00M+27.7%
Q4 FY2024Dec 31, 2024$164.65M+29.5%
Q3 FY2024Sep 30, 2024$139.49M+42.3%
Q2 FY2024Jun 30, 2024$147.03M+35.7%
Q1 FY2024Mar 31, 2024$108.83M+8.3%
Q4 FY2023Dec 31, 2023$127.14M+23.0%
Q3 FY2023Sep 30, 2023$98.05M+8.1%
Q2 FY2023Jun 30, 2023$108.31M+21.2%
Q1 FY2023Mar 31, 2023$100.50M+25.7%
Q4 FY2022Dec 31, 2022$103.35M+23.9%
Q3 FY2022Sep 30, 2022$90.70M+11.1%
Q2 FY2022Jun 30, 2022$89.34M+2.7%
Q1 FY2022Mar 31, 2022$79.94M-19.6%
Q4 FY2021Dec 31, 2021$83.39M-8.9%
Q3 FY2021Sep 30, 2021$81.65M+0.2%
Q2 FY2021Jun 30, 2021$86.98M+40.9%
Q1 FY2021Mar 31, 2021$99.40M+173.7%
Q4 FY2020Dec 31, 2020$91.54M+157.2%
Q3 FY2020Sep 30, 2020$81.47M+215.8%
Q2 FY2020Jun 30, 2020$61.71M+155.5%
Q1 FY2020Mar 31, 2020$36.31M+99.8%
Q4 FY2019Dec 31, 2019$35.59M+118.9%
Q3 FY2019Sep 30, 2019$25.80M+119.3%
Q2 FY2019Jun 30, 2019$24.15M+88.8%
Q1 FY2019Mar 31, 2019$18.17M+70.2%
Q4 FY2018Dec 31, 2018$16.26M+573.6%
Q3 FY2018Sep 30, 2018$11.76M+5840.9%
Q2 FY2018Jun 30, 2018$12.79M+255780.0%
Q1 FY2018Mar 31, 2018$10.68M+9518.9%
Q4 FY2017Dec 31, 2017$2.41M–
Q3 FY2017Sep 30, 2017$198.00K–
Q4 FY2016Dec 31, 2016$5.00K–
Q3 FY2016Sep 30, 2016$111.00K–

More Ultragenyx Pharmaceutical figures

See a number that looks wrong?